Schizophrenia Clinical Trials in Little Rock, Arkansas

16 studies are recruiting for schizophrenia in Little Rock, Arkansas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study of LTX-001 In Adult Participants With Acute Exacerbation of Schizophrenia

   The purpose of this clinical trial is to learn whether the investigational drug LTX-001 is safe and well tolerated in adults with a diagnosis of schizophrenia who are having a recent worsening of their symptoms (an acute exacerbation). Additional questions it aims to answer are: * how does the amou…

   Stage

   Phase 1

   Ages

   18 to 55

   Site

   Pillar Clinical Research, LLC, Little Rock, Arkansas

   Locations

   10 in total

   Run by

   Leal Therapeutics, Inc

   See if you can join NCT07734493 on ClinicalTrials.gov

2. A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia

   Schizophrenia is a common and severe psychiatric illness characterized by extreme disturbances of cognition and thought, affecting language, perception and sense of self. This study will assess adverse events, change in disease activity, and how oral emraclidine moves through the body in adult part…

   Stage

   Phase 2

   Ages

   18 to 65

   Site

   Woodland International Research Group /ID# 275747, Little Rock, Arkansas

   Locations

   7 in total

   Run by

   AbbVie

   See if you can join NCT07145918 on ClinicalTrials.gov

3. Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia

   The purpose of the study is to evaluate the relapse prevention of KarXT in the treatment of participants with Schizophrenia

   Stage

   Phase 3

   Ages

   18 to 65

   Site

   Pillar Clinical Research- Little Rock, Little Rock, Arkansas

   Locations

   59 in total

   Run by

   Karuna Therapeutics, Inc., a Bristol Myers Squibb company

   See if you can join NCT07686263 on ClinicalTrials.gov

4. 52-week Open Label Safety-Tolerability Study

   Phase 3, open label, multicenter study designed to assess the long term safety and tolerability of LB-102 for the treatment of adult patients with stable schizophrenia

   Stage

   Phase 3

   Ages

   18 to 65

   Site

   Pillar Clinical Research, Little Rock, Arkansas

   Locations

   23 in total

   Run by

   LB Pharmaceuticals Inc.

   See if you can join NCT07369154 on ClinicalTrials.gov

5. A Study of Brenipatide in Adult Participants With Schizophrenia

   The purpose of this study is to assess the efficacy and safety of brenipatide when administered with standard of care (SoC) compared to placebo plus SoC for treatment of schizophrenia. The trial is divided into three periods as follows: Screening period will last approximately 1 month, treatment pe…

   Stage

   Phase 2

   Ages

   18 to 55

   Site

   Pillar Clinical Research- Little Rock, Little Rock, Arkansas

   Locations

   103 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07410507 on ClinicalTrials.gov

6. A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia

   ML-007C-MA-212 is a 52-week open-label study designed to evaluate the long-term safety, tolerability, and effectiveness of ML-007C-MA in participants with schizophrenia who have recently completed an antecedent study (ML-007C-MA-211) or enroll directly (De Novo Cohort).

   Stage

   Phase 2

   Ages

   18 to 65

   Site

   Clinical Site, Little Rock, Arkansas

   Locations

   42 in total

   Run by

   MapLight Therapeutics

   See if you can join NCT07459647 on ClinicalTrials.gov

7. Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder

   This is a multicenter, global, 26-week, open-label study to assess the safety and tolerability of lumateperone in pediatric patients with schizophrenia, bipolar disorder or autism spectrum disorder.

   Stage

   Phase 3

   Ages

   5 to 17

   Site

   Pillar Clinical Research, LLC, Little Rock, Arkansas

   Locations

   64 in total

   Run by

   Intra-Cellular Therapies, Inc.

   See if you can join NCT06229210 on ClinicalTrials.gov

8. Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia

   The main objective of this Phase 2 study is to assess the efficacy of ublituximab as measured by Positive and Negative Syndrome Scale (PANSS) total score in participants with schizophrenia.

   Stage

   Phase 2

   Ages

   18 to 60

   Site

   TG Therapeutics Investigational Trial Site, Little Rock, Arkansas

   Locations

   2 in total

   Run by

   TG Therapeutics, Inc.

   See if you can join NCT07680946 on ClinicalTrials.gov

9. Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder

   To compare changes in body mass index (BMI) Z-score following treatment with OLZ/SAM vs olanzapine

   Stage

   Phase 3

   Ages

   10 to 17

   Site

   Alkermes Investigator Site, Little Rock, Arkansas

   Locations

   47 in total

   Run by

   Alkermes, Inc.

   See if you can join NCT05303064 on ClinicalTrials.gov

10. A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia

    Evaluate the efficacy and safety of Ulotaront (SEP-363856) in acutely psychotic subjects with schizophrenia

    Stage

    Phase 3

    Ages

    18 to 65

    Site

    Pillar Clinical Research (Little Rock AR) Site, Little Rock, Arkansas

    Locations

    73 in total

    Run by

    Otsuka Pharmaceutical Development & Commercialization, Inc.

    See if you can join NCT06894212 on ClinicalTrials.gov

11. Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia

    This is a Phase 3, randomized, double blind, placebo controlled, fixed dose, study designed to evaluate the efficacy, safety, tolerability, and of LB-102 versus placebo for the treatment of adult patients with an acute exacerbation of schizophrenia.

    Stage

    Phase 3

    Ages

    18 to 65

    Site

    Pillar Clinical Research, Little Rock, Arkansas

    Locations

    13 in total

    Run by

    LB Pharmaceuticals Inc.

    See if you can join NCT07363577 on ClinicalTrials.gov

12. NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia

    This study will evaluate the long-term safety of NBI-1117568 in adults with schizophrenia.

    Stage

    Phase 3

    Ages

    18 to 65

    Site

    Neurocrine Clinical Site, Little Rock, Arkansas

    Locations

    57 in total

    Run by

    Neurocrine Biosciences

    See if you can join NCT07114874 on ClinicalTrials.gov

13. A Study to Evaluate the Effect of KarXT on Urological Safety

    The purpose of this study is to characterize the effect of KarXT on voiding dynamics and urological safety in participants with DSM-5 schizophrenia.

    Stage

    Phase 4

    Ages

    18 to 65

    Site

    Pillar Clinical Research- Little Rock, Little Rock, Arkansas

    Locations

    13 in total

    Run by

    Bristol-Myers Squibb

    See if you can join NCT07221877 on ClinicalTrials.gov

14. NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia

    The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults.

    Stage

    Phase 3

    Ages

    18 to 65

    Site

    Neurocrine Clinical Site, Little Rock, Arkansas

    Locations

    21 in total

    Run by

    Neurocrine Biosciences

    See if you can join NCT06963034 on ClinicalTrials.gov

15. Safety and Tolerability of Open-Labeled Iloperidone in Adolescents

    To evaluate the safety and tolerability of iloperidone in adolescent patients with schizophrenia or bipolar I disorder for up to 52 weeks of treatment.

    Stage

    Phase 4

    Ages

    12 to 17

    Site

    Vanda Investigational Site, Little Rock, Arkansas

    Locations

    9 in total

    Run by

    Vanda Pharmaceuticals

    See if you can join NCT05648591 on ClinicalTrials.gov

16. Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia

    This study is to evaluate the effect and safety of Brilaroxazine in patients with acute schizophrenia compared to the placebo short and long-term. Brilaroxazine will be given at fixed doses of 15 mg or 50 mg once daily over 4 weeks, then in the long-term flexible doses 15-50mg daily over a period o…

    Stage

    Phase 3

    Ages

    18 to 65

    Site

    Reviva site, Little Rock, Arkansas

    Locations

    18 in total

    Run by

    Reviva Pharmaceuticals

    See if you can join NCT05184335 on ClinicalTrials.gov